BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

RNL Bio and Human Biostar to Offer Direct-to-Consumer Adult Stem Cell Banking in the United States


5/21/2013 9:30:58 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEOUL, South Korea, May 20, 2013 /PRNewswire/ -- RNL BIO Co. Ltd., a stem cell biotechnology company dedicated to the commercialization of autologous cell therapy products for a variety of degenerative, ischemic and other indications, announces the availability of adult stem cell banking in the United States beginning on June 20, 2013. RNL BIO previously offered these services through another company, but will now provide the latest, safest technologies directly. As the sole global provider of its stem cell banking services, RNL BIO will provide clients with continuous quality assurance and constant innovation in adult stem cell technologies.

RNL BIO operates facilities in Maryland, Los Angeles and a FDA-registered stem cell banking facility in the Houston, Texas metroplex. It has opened a 15,000 square foot GMP laboratory facility in Sugar Land, Texas with extensive, state-of-the-art stem cell research and banking equipment, staffed by highly qualified scientists.

No human mesenchymal stem cell-based drug is presently approved for treatment in the United States. The only pathway to legal stem cell therapy is through FDA-approved clinical trials. RNL BIO has filed an Investigational New Drug application (IND) with the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) to begin clinical trials with its adipose-derived stem cell product, termed Jointstem, for the treatment of osteoarthritis (OA). Phase 2 clinical trials of Jointstem and another autologous stem cell-based biologic Vascostem (for treatment of Buerger's disease) have been completed under the authority of the Korean Food and Drug Administration (KFDA) in Seoul, Korea. Having reached this stage, RNL BIO filed New Drug Applications (NDA) to authorize the clinical use of these mesenchymal stem cell products in Korea. RNL BIO will be working with the FDA to determine what level of investigational availability is possible for its adult stem cell biologics in certain intractable and incurable diseases where no other therapeutic modality is available.

"We are happy to begin providing clients in the United States with our stem cell banking services," said Jeong-Chan Ra, Ph.D., the CEO and Chairman of RNL BIO. "We want to advance both banking and FDA-approved uses of stem cell technology." During 2011-13, RNL BIO has published its studies in more than 20 articles in major peer-reviewed journals. "We are following the pathways to regulatory approval so that our banking program can expand to include approved biologics for use in the United States and Europe."

ACCESS TO BANKING

RNL BIO provides stem cells to physicians whose patients request that they be obtained, however RNL BIO and Human Biostar are not offering stem cell therapeutics in the United States. RNL BIO is joining with U.S. hospitals and physicians in its banking services and to researchers in its bench and clinical trial activities.

About RNL Bio

RNL BIO is a South Korean biotechnology company focused on the research and development of adult derived stem cell technologies. Its autologous, adipose-derived human mesenchymal stem cell technology, anchored by its unique stem cell culture media, is the subject of patents and patent applications in more than 30 nations and has been the subject of many scientific studies and peer-reviewed publications. The story of RNL BIO, its Chairman and its experiences with the use of stem cells in the clinical setting is the subject of the 2012 book, The grace of stem cells: a story of science and faith by J.C. Ra, available at bookstores and from Amazon.

Safe Harbor:This article may contain forward looking statements including projections and business trends. Actual results may differ materially from the anticipated results and expectations expressed in these forward-looking statements as a result of certain risks and uncertainties. These forward-looking statements are made based upon information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.

For more information visit http://www.rnl.co.kr/eng/main.asp, which is not part of this press release.

SOURCE RNL Bio



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

RNL Bio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES